

4DMedical investor webinar

Melbourne, Australia, 8 May 2023: Respiratory imaging technology company 4DMedical Limited (ASX:4DX, "4DMedical", or the "Company") is pleased to invite shareholders, investors and interested parties to its investor webinar hosted by the Chief Executive Officer, Andreas Fouras.

4DMedical will hold an investor webinar on Tuesday, 9 May 2023 at 11.00am AEST, where Andreas Fouras will discuss the Company's capital raise, focusing on the following:

- commercialisation in Australia;
- commercialisation in the U.S. and progress on reimbursement;
- update on the VA and Department of Defense opportunity; and
- upcoming milestones.

Investor Q&A will follow the presentation.

Investor Webinar Registration Details

An investor webinar with Andreas Fouras, Chief Executive Officer of 4DMedical will be held at 11.00am AEST on Tuesday, 9 May 2023.

Please register in advance using the following link:

https://s1.c-conf.com/diamondpass/10030704-eyqauv.html

After registering, you will receive a confirmation email containing information about joining the webinar as well as dial-in details for those who would prefer to join by telephone.

A recording will be available at the above link shortly after the conclusion of the live session.

-ENDS-

Authorised by the CEO.

Contacts

Corporate CFO Simon Glover sglover@4dmedical.com Administration Company Secretary Naomi Lawrie companysecretary@4dmedical.com Media Enquiries TCN Julia Maguire julia@thecapitalnetwork.com.au

The future of lung health

Melbourne Level 7 Melbourne Connect 700 Swanston Street Carlton VIC 3053 Tel: +61 (3) 9545 5940 Los Angeles 21255 Burbank Boulevard Suite 102 Woodland Hills CA 91367 Tel: +1 (818) 403-8490

4DMedical Limited ABN: 31 161 684 831 Email: info@4DMedical.com www.4DMedical.com



About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company that has created a step change in the capacity to accurately and quickly understand the lung function of patients with respiratory diseases.

Through its flagship patented XV Technology[®], 4DMedical enables physicians to understand regional airflow in the lungs and identify respiratory deficiencies earlier and with greater sensitivity as they breathe. This technology powers 4DMedical's FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS[®]) – the first modality to dynamically quantify ventilation throughout the lungs, and its Computed Tomography-enabled counterpart software, CT LVAS[™].

XV LVAS[®] and CT LVAS[™] reports are prepared using 4DMedical's Software as a Service delivery model using existing hospital imaging equipment or the Company's revolutionary XV Scanner.

To learn more, please visit <u>www.4dmedical.com.</u>